2e+40 Stock Overview
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.84 |
| 52 Week High | €10.26 |
| 52 Week Low | €2.75 |
| Beta | 1.79 |
| 1 Month Change | 0% |
| 3 Month Change | -20.00% |
| 1 Year Change | -71.37% |
| 3 Year Change | -94.75% |
| 5 Year Change | -95.80% |
| Change since IPO | -98.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2e+40 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -1.5% | 1.9% |
| 1Y | -71.4% | -23.6% | 4.6% |
Return vs Industry: 2E40 underperformed the German Biotechs industry which returned -23.6% over the past year.
Return vs Market: 2E40 underperformed the German Market which returned 4.6% over the past year.
Price Volatility
| 2e+40 volatility | |
|---|---|
| 2e+40 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2E40's share price has been volatile over the past 3 months.
Volatility Over Time: 2E40's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 68 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
| 2e+40 fundamental statistics | |
|---|---|
| Market cap | €17.86m |
| Earnings (TTM) | -€23.49m |
| Revenue (TTM) | €1.33m |
13.5x
P/S Ratio-0.8x
P/E RatioIs 2e+40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2e+40 income statement (TTM) | |
|---|---|
| Revenue | €1.33m |
| Cost of Revenue | €0 |
| Gross Profit | €1.33m |
| Other Expenses | €24.81m |
| Earnings | -€23.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -3.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,771.34% |
| Debt/Equity Ratio | 39.8% |
How did 2e+40 perform over the long term?
See historical performance and comparison